CMOTEC B Stock Overview
Offers cancer care and pain management solutions in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Scandinavian ChemoTech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.75 |
| 52 Week High | SEK 5.20 |
| 52 Week Low | SEK 1.60 |
| Beta | 1.37 |
| 11 Month Change | -8.38% |
| 3 Month Change | -15.87% |
| 1 Year Change | -27.39% |
| 33 Year Change | -90.33% |
| 5 Year Change | -82.76% |
| Change since IPO | -96.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| CMOTEC B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 5.4% | -2.6% | -0.2% |
| 1Y | -27.4% | -6.3% | 11.8% |
Return vs Industry: CMOTEC B underperformed the Swedish Medical Equipment industry which returned -7.8% over the past year.
Return vs Market: CMOTEC B underperformed the Swedish Market which returned 10.9% over the past year.
Price Volatility
| CMOTEC B volatility | |
|---|---|
| CMOTEC B Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: CMOTEC B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: CMOTEC B's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 5 | Stefan Frick | chemotech.se |
Scandinavian ChemoTech AB (publ) offers cancer care and pain management solutions in Sweden. The company offers IQWave, an electroporation device, used for electrochemotherapy and treatment of head and neck cancer, squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. It also offers Vetiqure for the treatment of superficial tumors in dogs, cats, and horses.
Scandinavian ChemoTech AB (publ) Fundamentals Summary
| CMOTEC B fundamental statistics | |
|---|---|
| Market cap | SEK 40.85m |
| Earnings (TTM) | -SEK 15.70m |
| Revenue (TTM) | SEK 5.03m |
8.1x
P/S Ratio-2.6x
P/E RatioIs CMOTEC B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMOTEC B income statement (TTM) | |
|---|---|
| Revenue | SEK 5.03m |
| Cost of Revenue | SEK 2.02m |
| Gross Profit | SEK 3.01m |
| Other Expenses | SEK 18.71m |
| Earnings | -SEK 15.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 04, 2025
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 59.88% |
| Net Profit Margin | -311.96% |
| Debt/Equity Ratio | 0% |
How did CMOTEC B perform over the long term?
See historical performance and comparison